QUINOX 750/MG FC TAB 10/FC TAB

Indications

Approved Uses

Urinary tract infections (complicated and uncomplicated), acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (with metronidazole), infectious diarrhea, typhoid fever, inhalational anthrax (post-exposure prophylaxis), plague, nosocomial pneumonia

Dosage & Administration

Initial Dose

500 mg to 750 mg every 12 hours (for most common indications)

Maintenance Dose

500-750mg every 12 hours depending on indication and severity

Children's Dosage

Not recommended for routine use in children under 18 years due to risk of arthropathy; approved for complicated UTI/pyelonephritis (6-17 years: 10-20mg/kg q12h, max 750mg/dose) and inhalational anthrax post-exposure (10-15mg/kg q12h, max 500mg/dose)

Dose Adjustment Notes

Dose adjustment is required in renal impairment (e.g., reduce dose and/or extend interval when CrCl ≤50 mL/min, with more significant adjustment when CrCl <30 mL/min); no routine adjustment is required for hepatic impairment, but use caution in severe hepatic disease.

How to Take

Swallow the 750 mg film‑coated tablet whole with water; may be taken with or without food. Avoid taking the dose with dairy products or calcium‑fortified juices alone, and separate from antacids/sucralfate or mineral supplements containing Mg/Al/Ca/Fe/Zn by at least 2 hours before or 6 hours after; maintain adequate hydration.

Side Effects

Common Side Effects

Nausea, diarrhea, vomiting, abdominal pain/discomfort, headache, dizziness, rash/photosensitivity, and transient elevations in liver enzymes (ALT/AST).

Side Effect Frequency

Common (1-10%): nausea, diarrhea (also vomiting/abdominal pain and CNS effects such as headache/dizziness are commonly reported in many product labels); Uncommon (0.1-1%): rash/pruritus and other GI/CNS effects; Rare/very rare (<0.1%): tendinitis/tendon rupture, peripheral neuropathy, seizures, QT prolongation, photosensitivity, severe hypersensitivity, and C. difficile-associated diarrhea/colitis.

Safety & Warnings

Contraindications

Contraindications: hypersensitivity to ciprofloxacin/other quinolones; concomitant use with tizanidine.

Warnings & Precautions

Precautions: tendonitis/rupture risk (higher in age >60, corticosteroids, transplant); peripheral neuropathy-stop if symptoms; CNS effects/seizure risk; avoid/monitor with QT prolongation risk factors; avoid in myasthenia gravis; C. difficile diarrhea; aortic aneurysm/dissection risk in susceptible patients; photosensitivity; dysglycemia; ensure hydration to reduce crystalluria.

Age Restriction

Not routinely recommended in patients <18 years; use only when benefits outweigh risks for specific approved/accepted pediatric indications (e.g., inhalational anthrax post-exposure, plague, and certain complicated UTI/pyelonephritis due to susceptible organisms when no safer alternatives).

Driving Warning

Not safe. Ciprofloxacin is associated with CNS adverse effects including dizziness, lightheadedness, hallucinations, confusion, and seizures, which may impair the ability to drive or operate machinery. Patients should be advised to avoid driving or operating machinery if these effects occur.

Special Populations

Children

Not recommended for routine use in children under 18 years due to risk of arthropathy; approved for complicated UTI/pyelonephritis (6-17 years: 10-20mg/kg q12h, max 750mg/dose) and inhalational anthrax post-exposure (10-15mg/kg q12h, max 500mg/dose)

Storage & Patient Advice

Stopping the Medicine

Complete the prescribed course unless a serious adverse reaction occurs (e.g., tendon pain/rupture, neuropathy, severe allergy, severe diarrhea), in which case stop and seek urgent medical advice.

Monitoring Requirements

No routine labs are required for all patients, but monitor: renal function in renal impairment/elderly or prolonged therapy; INR if on warfarin; blood glucose in diabetics (dysglycemia risk); theophylline levels/clinical toxicity if co-administered; and clinically monitor for tendinopathy, peripheral neuropathy, CNS effects, severe diarrhea (C. difficile), and hypersensitivity.

Pharmacology

Onset of Action

Peak plasma concentrations occur about 1-2 hours after an oral dose; clinical improvement is typically seen within 24-72 hours depending on infection and source control.

Product Information

Available Dosage Forms

For this product (SFDA: QUINOX 750MG F‑C TABLET): film‑coated tablet (oral). For ciprofloxacin in general: immediate‑release tablets, extended‑release tablets, oral suspension, IV infusion/solution, ophthalmic solution (eye drops), otic solution (ear drops).

Composition per Dose

Each film-coated tablet: 750mg ciprofloxacin (as ciprofloxacin hydrochloride)

Generic Availability

Yes

Spectrum

Broad-spectrum, with excellent activity against Gram-negative bacteria (including Pseudomonas aeruginosa) and moderate activity against some Gram-positive bacteria.

Antibiotic Class

Fluoroquinolone

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 21-05-2026